FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 03:03:14 2024-05-23 am EDT | ||
| 3.91 EUR / 3.93 EUR | -0.76% |
|
| Current month | -50.75% | ||
| 1 month | -60.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 3.95 | -11.63% |
| 24-05-21 | 4.47 | +3.00% |
| 24-05-20 | 4.34 | -12.50% |
| 24-05-17 | 4.96 | +12.47% |
| 24-05-16 | 4.41 | +5.50% |
Delayed Quote Börse Stuttgart
Last update May 22, 2024 at 03:13 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF6 |
| ISIN | DE000MG1SF66 |
| Date issued | 2024-04-05 |
| Strike | 1,030 kr |
| Maturity | Unlimited |
| Parity | 3.65 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.95 € |
|---|---|
| Lowest since issue | 3.88 € |
| Spread | 0.07 € |
| Spread % | 1.67% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- Certificat
